Janssen’s Ponvory (ponesimod) Receives the US FDA’s Approval for the Treatment of Relapsing Multiple Sclerosis

 Janssen’s Ponvory (ponesimod) Receives the US FDA’s Approval for the Treatment of Relapsing Multiple Sclerosis

Janssen’s Ponvory (ponesimod) Receives the US FDA’s Approval for the Treatment of Relapsing Multiple Sclerosis

Shots:

  • The approval is based on the P-III head-to-head OPTIMUM trial involves assessing Ponvory (20 mg) vs Teriflunomide (14 mg) in adults with relapsing MS and follows >10 yrs of cumulative data demonstrating its efficacy and safety
  • The results demonstrated superior efficacy in reducing annual relapses by 30.5%, no confirmed relapses (30.5% vs 61%), reducing the number of new GdE T1 lesions and the number of new or enlarging T2 lesions by 59% and 56%, confirmed disability progression
  • Ponvory (ponesimod) is a selective S1P1 modulator to treat adults with relapsing MS and is the 1st and only FDA-approved oral disease modifying therapy studied against an established oral comparator

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Brightfox

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post